Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Human erythropoietin (EPO) is a potent neuroprotective agent for multiple brain disorders, including stroke, brain and spinal cord injury, and Parkinson's disease. However, EPO drug development for the brain is limited, because EPO does not cross the blood-brain barrier (BBB). In acute stroke or brain injury, the BBB is intact in the early hours after the insult when neuroprotection is still possible. Therefore, large molecule biopharmaceuticals such as EPO must be re-engineered to enable BBB transport.

17 Jul 2010

Amgen granted FDA priority review designation for denosumab BLA

Amgen today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with cancer.

17 Jul 2010

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses.

16 Jul 2010

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthrax. Under the new contract, Lonza will provide process scale-up, technology transfer, validation, and commercial manufacturing at one of its facilities in the USA. The manufacturing process for Anthim was optimized for full scale production by Lonza under a separate agreement announced in 2009.

16 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Amorfix Life Sciences Ltd. today announced that it has entered into a licensing agreement granting Biogen Idec exclusive worldwide rights to Amorfix's lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. The antibodies have shown efficacy in animal models of ALS and Biogen Idec will now, at its expense, complete the development and prepare for clinical trials.

15 Jul 2010

Hendra virus treatment to be ready in a few months

Of the dozen people who were exposed to a horse infected with the Hendra virus, 11 have been cleared of the infection by repeated tests on Queensland's Sunshine Coast. These 12 people had first come into contact with the infected horse at Tewantin in May and have since then been subjected to testing to rule out infection with the deadly virus. It is expected that the 12th person will also be cleared soon. Quarantine restrictions were also lifted last month.

14 Jul 2010

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

BioInvent reached an important milestone when the results of a phase II trial of TB-402 following orthopaedic surgery, were reported in May. The data showed that TB-402 is statistically better at preventing thrombosis than enoxaparin, the current standard treatment. Supported by these good results, BioInvent and the company's partner, ThromboGenics, will now prioritise securing a development partner for the programme to ensure that the necessary resources is in place to take the product candidate to the market.

14 Jul 2010

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease, today announced that it is pleased with the recent press coverage the Company and Dr. Daniel G. Chain, Ph.D., the Company's Chairman and Chief Executive Officer, recently has received.

14 Jul 2010

Scientists discover three human antibodies that neutralize HIV

Scientists have discovered three previously unknown human antibodies that neutralize HIV, two of which target a broad range of HIV strains. The findings, reported online July 8 in two Science papers, add a level of encouragement to the AIDS vaccine research field.

14 Jul 2010

Researcher to lead $14.5M project to fight malaria in Southeast Asia

A researcher in Penn State's College of Agricultural Sciences will lead a seven-year, $14.5 million project to fight malaria in Southeast Asia. Liwang Cui, professor of entomology, is the principal investigator for the Southeast Asia Malaria Research Center, one of 10 International Centers of Excellence for Malaria Research announced by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

14 Jul 2010

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Human Genome Sciences, Inc. and Lonza today announced an agreement for the future commercial supply of BENLYSTA® (belimumab), which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE). BENLYSTA is being developed by HGS and GlaxoSmithKline (GSK) under a co-development and commercialization agreement entered into in 2006.

13 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

Phase II trial results of TB-402 presented at International Congress on Thrombosis

BioInvent International AB and ThromboGenics NV announce that the positive results from a Phase II trial of TB-402 (Anti-Factor VIII antibody) were presented at the 21st International Congress on Thrombosis in Milan, Italy yesterday. TB-402 is a novel, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism following orthopaedic surgery.

9 Jul 2010

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies using its proprietary SIMPLE Antibody(TM) platform, announces that it has been granted the first patent covering the platform. The patent GB2461546B, has been granted by the UK Patent and Trademark Office (UKPTO).

9 Jul 2010

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats, announced today that it continues to make solid progress in its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine development program. The Company has recently demonstrated that its lyophilized rPA vaccine candidate is structurally stable and potent at various temperatures up to and including 70 degrees centigrade.

9 Jul 2010

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the launch of its new ProRes-S media. With the addition of ProRes-S media, Millipore's purification suite now provides a complete solution for the downstream purification of monoclonal antibodies and proteins. Developed jointly with The Dow Chemical Company, ProRes-S media offers biopharmaceutical manufacturers greater flexibility and increased throughput in a smaller manufacturing footprint.

8 Jul 2010

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

The combination of Biothera's experimental drug Imprime PGG® and Erbitux® (cetuximab) doubled the historical overall response rate and the time to progression of second- and third-line metastatic colorectal cancer patients treated with Erbitux monotherapy. The data was released last weekend at the 13th World Congress on Gastrointestinal Cancer at the European Society for Medical Oncology (ESMO).

7 Jul 2010

Initial Phase II study results of ofatumumab in patients with RRMS announced

Genmab A/S announced today positive interim results from an ofatumumab Phase II safety and pharmacokinetics study in patients with relapsing-remitting multiple sclerosis.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

Monoclonal Antibody News and Research

Further Reading

ArmaGen uses BBB molecular Trojan horse platform technology to create brain penetrating form of human EPO

Amgen granted FDA priority review designation for denosumab BLA

Lyophilized rPA anthrax vaccine more immunogenic than liquid formulation: Study

Elusys, Lonza partner for commercial production of Anthim antibody for inhaled anthrax treatment

NIH awards MacroGenics $9.8 million grant for three projects

Amorfix grants Biogen Idec exclusive worldwide rights to lead ALS monoclonal antibodies

Hendra virus treatment to be ready in a few months

BioInvent reports net revenues of SEK 63.1M for January - June 2010 period

Media outlets focus on audiences towards Alzheimer's disease: Intellect Neurosciences

Scientists discover three human antibodies that neutralize HIV

Researcher to lead $14.5M project to fight malaria in Southeast Asia

Human Genome Sciences, Lonza announce commercial supply agreement for BENLYSTA

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Phase II trial results of TB-402 presented at International Congress on Thrombosis

UKPTO grants arGEN-X patent covering SIMPLE Antibody platform

PharmAthene reports progress in lyophilized rPA anthrax vaccine development program

Millipore launches new ProRes-S media for downstream purification of monoclonal antibodies, proteins

Combination of Biothera's Imprime PGG and Erbitux doubles response rate in colorectal cancer patients

Initial Phase II study results of ofatumumab in patients with RRMS announced

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Monoclonal Antibody Manufacturing Trends eBook eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News